retatrutide ly3437943 clinical trials Results: 28.3% Weight Loss Data retatrutide trials sign up VisualAbstract:

New England Journal of Medicine 2023 03 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial Rosenstock J, Frias J, Jastreboff AM, et al

Secondary interactions: Residual silanols or trace metals can alter peak shapes or delay elution

Tirzepatide also has a significantly longer half-life of approximately 5 days, which allows for once-weekly dosing

However, its therapeutic efficacy may be influenced by population-specific characteristics, though, as seen by variations in composition, dose, and starting deficient status among investigations

It is safe to use if you use it carefully in your routine